Morgan Stanley Reaffirms Their Hold Rating on Pfizer (PFE)
UBS Maintains Pfizer(PFE.US) With Hold Rating, Cuts Target Price to $24
Pfizer Cut to Neutral From Buy by Goldman Sachs
Pfizer Price Target Cut to $25.00/Share From $32.00 by Goldman Sachs
Pfizer Analyst Ratings
UBS Adjusts Price Target on Pfizer to $24 From $28, Keeps Neutral Rating
Goldman Sachs Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $25
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34
Jefferies Sticks to Its Buy Rating for Pfizer (PFE)
J.P. Morgan Maintains Pfizer(PFE.US) With Hold Rating, Announces Target Price $30
J.P. Morgan Remains a Hold on Pfizer (PFE)
Bernstein Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Bernstein Sticks to Its Hold Rating for Pfizer (PFE)
Citi Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27
Pfizer (PFE) Receives a Hold From Citi
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE), Nanobiotix (NBTX) and PTC Therapeutics (PTCT)
DBS Initiates Pfizer(PFE.US) With Buy Rating, Announces Target Price $30
Pfizer's Strong Financial Performance and Strategic Developments Drive Buy Rating
BofA Securities Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $29
Hold Rating Maintained for Pfizer Amid Revenue Concerns and Limited Catalysts